Abnormal long-chain
fatty acid metabolism has been suggested as having a role in the genesis of certain
cardiac diseases, and depressed myocardial long-chain
fatty acid uptake has been clinically demonstrated in some patients with
hypertrophic cardiomyopathy. However, the site where long-chain
fatty acid metabolism is affected in
cardiomyopathy remains unclear. Although
cardiac hypertrophy is reported to be induced in rats by a
fat-free diet, little is known of the consequences of depressed myocardial long-chain
fatty acid uptake. Sulfo-N-succinimidyl derivatives of long-chain
fatty acids have been shown to irreversibly inhibit long-chain
fatty acid transport. To investigate the possible linkage of abnormal long-chain
fatty acid uptake with
cardiac hypertrophy, myocardial long-chain
fatty acid uptake was blocked in rats using a sulfo-N-succinimidyl derivative of
palmitate (SSP). SSP was intraperitoneally administered to rats for 12 weeks, and its effects on physiological parameters, and cardiac morphology were studied, SSP treatment (20 mg/kg) caused a 12% increase in heart weight (663.7 +/- 33.6 mg in controls v 741.2 +/- 26.5 mg after SSP treatment) and an 11% increase in the heart weight to
body weight ratio (2.46 +/- 0.10 in controls v 2.72 +/- 0.17 after SSP) without any significant change of
body weight. No significant differences were observed in blood pressure, heart rate, and serum
hormones (
insulin and
triiodothyronine) between the control and SSP-treated groups.(ABSTRACT TRUNCATED AT 250 WORDS)